Adrian Newland
Queen Mary University of London
H-index: 72
Europe-United Kingdom
Top articles of Adrian Newland
Overview of the Safety Profile from Efgartigimod Clinical Trials in Participants with Diverse IgG-mediated Autoimmune Diseases (P4-14.016)
SKIN The Journal of Cutaneous Medicine
2024/1/16
Autoimmune hematological disorders
Molecular Hematology
2024/4/2
Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study)
Hematology
2023/12/31
Adrian Newland
H-Index: 29
Treatment preferences towards thrombopoietin-receptor agonists for immune thrombocytopenia and experience of disease (TRAPeze): Italy cohort
Hematology
2023/12/31
Adrian Newland
H-Index: 29
Overview of the safety profile of efgartigimod from clinical trials in participants with diverse immunoglobulin G–mediated autoimmune diseases
Journal of the Neurological Sciences
2023/12/1
Time to achieve Platelet count response after intravenous Efgartigimod in adults with primary immune thrombocytopenia: a phase 3, multicenter, double-blinded, placebo …
Blood
2023/11/28
Hanny Al-Samkari
H-Index: 17
Adrian Newland
H-Index: 29
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo …
The Lancet
2023/11/4
S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY
HemaSphere
2023/8/1
Hanny Al-Samkari
H-Index: 17
Adrian Newland
H-Index: 29
P. 045 Safety profile overview of Efgartigimod Clinical Trials in participants with diverse Diverse IgG-Mediated Autoimmune Diseases
Canadian Journal of Neurological Sciences
2023/6
584 Overview of the safety profile of efgartigimod from clinical trials in participants with diverse IgG–mediated autoimmune diseases
Journal of Investigative Dermatology
2023/5/1
Current concepts in the diagnosis and management of adult primary immune thrombocytopenia: our personal view
2019/4/15
Pcr246 patient preferences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in Italy (TRAPeze Italy study)
2022/12/1
Efficacy and safety of intravenous efgartigimod in adults with primary immune thrombocytopenia: results of a phase 3, multicenter, double-blinded, placebo-controlled …
Blood
2022/11/15
Incidence of adult primary immune thrombocytopenia in England—An update
European Journal of Haematology
2022/9
Nicola Cooper
H-Index: 35
Adrian Newland
H-Index: 29
Investigational drugs for immune thrombocytopenia
2022/7/3
P1636: PATIENT PREFERENCES AND EXPERIENCES REGARDING THROMBOPOIETIN-RECEPTOR AGONISTS FOR IMMUNE THROMBOCYTOPENIA IN THE NETHERLANDS (TRAPEZE NL STUDY).
HemaSphere
2022/6/1
Adrian Newland
H-Index: 29
Real world evidence from the UK ITP Registry on the effectiveness of the immunosuppressive therapies rituximab and mycophenolate mofetil in immune thrombocytopenia
2022/4
SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP
Blood, The Journal of the American Society of Hematology
2022/3/10
Paradigm shift in ITP treatment patterns in the era of the COVID-19 pandemic-opportunity to study real world outcomes from an established platform: Update from UK Adult ITP …
Research and Practice in Thrombosis and Haemostasis Conference
2022
Sars-cov-2 vaccination in patients with pre-existing immune thrombocytopenia
Blood
2021/11/23
